Healthcare, Pharma & Life Sciences

Emboline Logs First U.S. Commercial Use of Emboliner Protection System

Santa Cruz, Calif. – October 02, 2026 -- Emboline, Inc. completed the first commercial use of its Emboliner® Embolic Protection System in the United States on October 1, 2026, just weeks after receiving U.S. Food and Drug Administration 510(k) clearance.

Two TAVR procedures mark Emboline's commercial debut

The device was deployed during two transcatheter aortic valve implantation (TAVR) procedures performed by Tamim Nazif, MD, Co-Director of the Structural Heart and Valve Center at New York-Presbyterian/Columbia University Irving Medical Center. Dr. Nazif also serves as Co-Principal Investigator of the PROTECT H2H clinical trial, which evaluated the Emboliner's performance ahead of regulatory approval.

Smartee Launches Two Orthodontic Systems at First Overseas Summit

Image
Smartee Launches Two Orthodontic Systems at First Overseas Summit

Palma de Mallorca, Spain – October 02, 2026 -- Smartee Denti-Technology concluded its first large-scale academic summit held outside China on September 19, drawing nearly 300 orthodontic clinicians from 27 countries to Palma de Mallorca and unveiling two new clear-aligner product systems for international markets.

Smartee debuts SA/SA Plus and AG KIDS systems at two-day event

The Smartee European Summit 2026 served as the international launch platform for Smartee SA/SA Plus, a clear-aligner system incorporating a locking mechanism to address primary snoring and mild-to-moderate obstructive sleep apnea alongside orthodontic treatment. The company also introduced Smartee AG KIDS, a craniofacial growth guidance system for patients aged 3 to 16 that targets sagittal, vertical and transverse growth management paired with orofacial myofunctional training appliances.

Marengo's Invikafusp Alfa-TRODELVY Combo to Debut Data at SITC 2026

Image
Marengo's Invikafusp Alfa-TRODELVY Combo to Debut Data at SITC 2026

Cambridge, Mass. – October 02, 2026 -- Marengo Therapeutics will present interim results from its STARt-002 trial combining invikafusp alfa with Gilead's TRODELVY (sacituzumab govitecan-hziy) at the Society for Immunotherapy of Cancer's 41st Annual Meeting in Phoenix, Arizona, November 4-8, 2026.

STARt-002 pairs a T-cell agonist with an antibody-drug conjugate for the first time in clinical testing

The Phase 1b/2 study tests invikafusp alfa, a Vβ6-selective dual T-cell agonist, alongside TRODELVY's TROP2-directed cytotoxic payload delivery. Marengo's Chief Medical Officer Kevin Chin said the ADC is designed to release tumor antigens and inflame the tumor microenvironment, priming less immunogenic tumors for T-cell-mediated responses that invikafusp alfa can then amplify.

AKASA Launches Autonomous AI Coding Covering 10% of U.S. Discharges

Image
AKASA Launches Autonomous AI Coding Covering 10% of U.S. Discharges

South San Francisco, Calif. – October 02, 2026 -- AKASA has launched an autonomous AI platform for inpatient medical coding and clinical documentation integrity (CDI), expanding beyond its existing prebill review tools after inpatient volume processed by the company grew nearly 6x over the past year.

AKASA's health system customers now cover 10% of U.S. inpatient discharges

The company's customer base collectively represents more than $180 billion in aggregate net patient revenue and roughly 10% of all U.S. inpatient discharges. The growth has been driven by adoption of AKASA's existing AI-powered prebill review products, which the company says created the volume and performance data needed to move into fully autonomous coding.

Quotient Sciences, Acesion Pharma Partner on AI Drug Formulation

Image
Quotient Sciences, Acesion Pharma Partner on AI Drug Formulation

Nottingham, England – October 02, 2026 -- Quotient Sciences and Copenhagen-based Acesion Pharma have launched a collaboration to apply AI-enhanced formulation development to Acesion's early-stage pipeline of small molecules targeting atrial fibrillation, a condition affecting an estimated 50-60 million people globally.

AI tool uses Bayesian optimization to screen drug formulations for clinical success

The collaboration deploys Quotient Sciences' new AI-enhanced formulation development solution within its Translational Pharmaceutics platform, applying active machine learning with Bayesian optimization to identify and prioritize drug products most likely to succeed in clinical testing. The approach is designed to compress early clinical decision-making timelines for sponsors developing new treatments.

Tianjin University's BCI Device Cuts Diagnosis Time to 30 Minutes

Tianjin, China – October 02, 2026 -- Tianjin University's "Shengong-Shengao" system has become China's first approved brain-computer interface (BCI) medical device for diagnosing cognitive impairment, cutting diagnosis time for conditions like hydrocephalus from days to just 30 minutes. The milestone marks a commercial breakthrough as TJU, China's first modern university, marks its 131st anniversary on October 2, 2026.

Shengong device line moves from lab to clinical wards nationwide

Developed by a team led by Professor Liu Xiuyun, the Shengong-Shengao system received regulatory approval and has already been joined by more than 20 additional devices in the Shengong series now deployed in clinical settings. The university states the devices have delivered measurable benefits to thousands of patients, signaling rapid translation of university research into deployable medical hardware.

Ascletis' ASC36_35FDC Shows Stronger Weight Loss Than Rival Combos in Preclinical Data

Image
Ascletis' ASC36_35FDC Shows Stronger Weight Loss Than Rival Combos in Preclinical Data

Hong Kong – – October 02, 2026 -- Ascletis Pharma Inc. (HKEX: 1672) presented preclinical data showing its ASC36_35FDC injectable combination drove a 24.8% body-weight reduction in a diet-induced obesity rat model on Day 14, outperforming two competitor co-formulations tested under identical dosing conditions.

The data were unveiled in a short oral discussion at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting, held September 28–October 2, 2026, in Milan, Italy.

Amen Clinics Study Finds Postpartum Depression Has Distinct Brain Patterns

Image
Amen Clinics Study Finds Postpartum Depression Has Distinct Brain Patterns

Costa Mesa, Calif. – October 02, 2026 -- Nearly 40% of women with postpartum depression showed a hyperfrontal/anterior cingulate cortex brain-activity pattern, more than double the 19.4% rate found in patients with major depression, according to new research from Dr. Daniel Amen and colleagues at Amen Clinics.

Brain scan comparison covers 26,135 patients across two depression groups

Researchers analyzed brain SPECT imaging scans from 58 women diagnosed with postpartum depression (PPD) and compared them against scans from 26,077 people with major depression. Each scan was classified into one of six brain-function categories: hyperfrontal/ACC, limbic, hypofrontal, toxic/diffuse low perfusion, brain trauma/acquired injury, or mixed patterns.

Lundbeck to Present Phase III MSA Data, Parkinson's Pipeline at MDS 2026

Valby – October 02, 2026 -- H. Lundbeck A/S will present late-breaking Phase III data on its multiple system atrophy (MSA) drug candidate amlenetug alongside new Parkinson's disease pipeline results at the International Congress of Parkinson's Disease and Movement Disorders (MDS) 2026 in Seoul, South Korea, running October 4-8.

MASCOT trial enrolled 401 participants across a global Phase III program

The late-breaking oral presentation will detail baseline characteristics of participants in MASCOT (NCT06706622), Lundbeck's ongoing Phase III trial of amlenetug in MSA. The trial enrolled 401 participants with clinically probable or established MSA, covering both MSA-C and MSA-P subtypes, across sites in North America, Europe, Asia and Australia. The double-blind treatment period runs 72 weeks, comparing high- and low-dose amlenetug against placebo, with results expected in Q3 2027.

Samfara Acquires Danish Controlled-Substance API Maker Chr. Olesen Synthesis

Image
Samfara Acquires Danish Controlled-Substance API Maker Chr. Olesen Synthesis

London – October 02, 2026 -- Samfara has completed the acquisition of Chr. Olesen Synthesis, a Danish manufacturer of controlled-substance active pharmaceutical ingredients, marking the London-based life sciences investment firm's first deal. The transaction sees Samfara buy the business from Chr. Olesen and funds managed by Signet Healthcare Partners, with Chief Executive Thomas Moestrup co-investing alongside the new owner. Financial terms were not disclosed.

Chr. Olesen Synthesis supplies opioid-disorder and ADHD treatment ingredients globally

Based near Copenhagen, Chr. Olesen Synthesis develops and manufactures APIs and advanced intermediates specialising in controlled substances, including buprenorphine for opioid use disorder and lisdexamfetamine for ADHD. Its cGMP-certified plant in Hvidovre has been in commercial production since 2015, supplying pharmaceutical companies across Europe, North America and the Middle East.